Posts filtered by tags: Merck[x]


Why anti-vaxxer mobs go after pro-vaccine doctors online — and what to do about it

In 2017, Kids Plus Pediatrics, an independent medical practice in Pittsburgh, posted a 90-second video on its Facebook page encouraging parents to have their children vaccinated against human papillomavirus (HPV), a sexually transmitted infection that can cause cancer.  For three weeks, the post garnered positive, higher-than-average interest and engagement from the page's followers. Then, seemingly out of nowhere, the anti-vaccination attacks began. Thousands of comments from vaccine skept...
Tags: Google, Facebook, Science, Youtube, Merck, Cnn, Italy, Donald Trump, Unicef, Pittsburgh, University of Pittsburgh, Vermont Sen Bernie Sanders, Sanofi, University of Pittsburgh School of Medicine, Hermann, Federation University Australia

Merck to collaborate with GenScript for plasmid and virus manufacturing in China

Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.
Tags: Health, China, Merck, GenScript

Cold Gensys raises $22 mln

Cold Gensys Inc said March 18 that it raised $22 million in a Series C round led by ORI Healthcare Fund LP. Perseverance Capital Management participated in the round. Cold Genesys is a clinical-stage biopharmaceutical company focused on the development of immunotherapies. PRESS RELEASE SANTA ANA, Calif.–(BUSINESS WIRE)–Cold Genesys, Inc., a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies, today announced the closing of a $22 million Series C preferred...
Tags: Trends, Merck, Simone, Gensys Inc, Calif BUSINESS WIRE Cold Genesys Inc, Cold Genesys, NMIBC Cold Genesys, Arthur Kuan, About Cold Genesys Cold Genesys, Simone Hong Fang Song, China Healthcare

Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Tags: Science, Merck, Eu, KEYTRUDA, Merck MRK

Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George...
Tags: Deals, Startups, China, Ipo, Cancer, Trends, Investing, Merck, Colorectal Cancer, Multiple Sclerosis, Harvard University, Health Insurance, Astrazeneca, Center For Medicare And Medicaid Services, Fda, National

Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials

TriNetX, a Cambridge, MA developer of data analytics software for clinical research, has raised $40 million in a Series D funding round led by Merck’s corporate venture capital fund, the company said.The company’s analytics platform helps pharma companies detail the many aspects of a clinical trial—from choosing hospital locations with adequate populations of patients to managing what age ranges and other demographic variables to include in the studies—to cut down on delayed studies due to a re...
Tags: Deals, Boston, Massachusetts, Trends, Merck, Artificial Intelligence, Venture Capital, Cambridge, Machine Learning, Novartis, Pfizer, Delays, Protocol, Electronic Health Records, Amendments, Sanofi

Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark

Could a shareholder revolt doom the planned marriage of Bristol-Myers Squibb and Celgene? Analysts have hinted at the possibility since the two companies shook hands in January, but the threat became real this week.Bristol (NYSE: BMY) and Celgene (NASDAQ: CELG) have campaignned heavily, starting with a joint presentation by their CEOs at the J.P. Morgan Healthcare Conference in January. Celgene drugs that should come to market the next two years will unlock $15 billion in annual revenue. The co...
Tags: Deals, Startups, Ge, Trends, Merck, Vc, Astrazeneca, Fda, National, Bristol, Novartis, Pfizer, Life Sciences, Clinical Trials, Celgene, Amgen

Germany's Merck makes $5.9 bln counterbid for Versum

German drugs and lab supplies maker Merck KGaA offered $5.9 billion, including debt, for Versum Materials, in a cash deal that tops an offer from U.S. rival Entegris, as both seek to boost their electrochemicals operations.
Tags: Money, Germany, Merck, businessNews, Merck KGaA, Entegris

Germany's Merck makes $5.9 billion countrebid for Versum

German drugs and lab supplies maker Merck KGaA offered $5.9 billion (4.4 billion pounds), including debt, for Versum Materials, in a cash deal that tops an offer from U.S. rival Entegris, as both seek to boost their electrochemicals operations.
Tags: Money, Germany, Merck, businessNews, Merck KGaA, Entegris

AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.
Tags: Science, Merck, Lynparza, AstraZeneca Merck, AstraZeneca AZN

Pharma companies want the government to do something about high drug prices, so long as it's not forcing them to lower their drug prices

Pharmaceutical CEOs and executives from seven companies went in front of Congress on Tuesday   to testify about the high price of prescription drugs. Over the course of a few hours, senators grilled the executives about the role they play in setting high prices for Americans as well as what they could do to fix it.  Toward the end, the executives seemed to reach a consensus that it'll take government action to solve the conundrum of how we get to lower prices.  One government action they don't...
Tags: Congress, Oregon, US, America, Trends, Merck, Iowa, Chuck Grassley, Astrazeneca, Medicare, Pascal Soriot, Wyden, Kenneth Frazier, Ron Wyden, Trump, Mylan

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

The growing epidemic of the fatty liver disease known as NASH, which has no FDA-approved treatment, has led to a frenzied race among drug companies. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?Intercept (NASDAQ: ICPT) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. The results should be enough to support an appr...
Tags: Deals, Startups, Drugs, Cancer, Trends, Investing, Merck, Leukemia, Acne, Inflammatory Bowel Disease, Xerox, Astrazeneca, Fda, National, Pfizer, Abbvie

Seattle biotech’s shares quadruple on news of buyout by Merck

Merck and Immune Design said Thursday they've struck a definitive agreement that will pay $5.85 per share in cash for Immune Design, an approximate value of $300 million.
Tags: Business, Technology, News, Merck, Seattle

Merck Scooping Up Cancer Drug Developer Immune Design for $300M

Four months after Immune Design halted a late-stage study for its lead cancer vaccine and saw its stock price cut nearly in half, the immunotherapy company is now in line to join Merck’s pipeline in a deal worth approximately $300 million.Merck (NYSE: MRK announced Thursday that it has agreed to pay $5.85 per share in cash to acquire Immune Design (NASDAQ: IMDZ). Shares of the Seattle company, which also has operations in South San Francisco, CA, closed at $1.42 on Wednesday.Immune Design devel...
Tags: Deals, New York, Drugs, Cancer, Trends, Merck, Fda, Biotech, Seattle, Lymphoma, Life Sciences, Clinical Trials, Roche, South San Francisco CA, MRK, National blog main

Pharma giants like Novartis and Sanofi are betting that the future of healthcare looks more like an app or sensor than a prescription

Drugmakers that got their start making pills and injections worth billions are turning their attention to digital therapeutics, enabled by new technology.  Their thinking is that pharmaceuticals can only take us so far, and it's up to drugmakers and potentially technology companies to come together and figure out how to push that envelope. For instance, Japanese pharma company Otsuka got approval for a version of an antipsychotic drug embedded with a sensor that can tell doctors if you've take...
Tags: Apple, Berlin, Digital, US, Trends, Merck, Pwc, Silicon Valley, Fda, Novartis, Shire, Young, Bayer, Parkinson, Johnson Johnson, Sanofi

Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study

Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Tags: Science, Merck, Fda, KEYTRUDA

Merck's Keytruda fails late-stage study in liver cancer patients

(Reuters) - Merck & Co Inc said on Tuesday its cancer drug Keytruda failed the main goals of a late-stage trial and did not extend life of patients with a type of liver cancer. The study was testing the drug in patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, against patients given a placebo plus best supportive care. Keytruda had earlier received an accelerated approval to treat patients with the liver cancer who had been previously treated with...
Tags: Science, Merck, Bengaluru, Bayer AG, KEYTRUDA, REUTERS Merck Co Inc, Tamara Mathias

Decades ago, ecstasy — yes, MDMA — was used in marriage counseling

For the first decade after it was synthesized, MDMA was used in individual and couples therapy.Many therapists spoke against the criminalization of MDMA in 1985 due to the drug's therapeutic potential.A revival has occurred in recent years, with the government allowing clinical trials to move forward. None Before the second "M" was affixed to "MDA," researchers spent decades searching for a utility for the mescaline derivative. Patented as "methylsafrylamin" in 1914 by Merck, the drug was shelv...
Tags: Marriage, California, Sex, Relationships, Love, Communication, Merck, Reagan, Vulnerability, Innovation, DEA, Derek, Mdma, Nixon, U S Army, MDA

Merck Gets Priority Review for Keytruda Combo in Kidney Cancer

Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Tags: Science, Merck, Fda, Pfizer, KEYTRUDA, Merck Gets Priority Review

Merck, Pfizer drug combo extends kidney cancer survival: study

Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent. The findings add to an arsenal of positive clinical data for Keytruda, which is approved to treat several types of cancer, making it ...
Tags: Science, Merck, Merck Pfizer

Merck to further study Keytruda in prostate cancer after early success

(Reuters) - Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial. The interim findings of the trial testing Keytruda in combination with other cancer drugs such as Lynpraza, which it jointly develops and sells with AstraZeneca, and chemotherapy docetaxel showed anti-tumor activity, Merck said. "These promising data .. ...
Tags: Science, Merck, Astrazeneca, KEYTRUDA, REUTERS Merck Co Inc

Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Tags: Science, Merck, Fda, KEYTRUDA

Merck, Pfizer combo treatment boosts kidney cancer survival

Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent. Merck said the treatments when used as the initial treatment for advanced renal cell carcinoma (RCC) reduced the risk of death by about 47 percent in its late-stage trial. Keytruda has been Merck's most important growth dr...
Tags: Science, Merck, RCC, KEYTRUDA, Pfizer Inc, Merck Co Inc, Inlyta, Merck Pfizer

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug - known as M7824, or bintrafusp alfa - and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck could als...
Tags: Science, Germany, Merck, GlaxoSmithKline, GSK, Merck KGaA

Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug known as M7824 and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck will also be eligible for further paymen...
Tags: Science, Germany, Merck, GlaxoSmithKline, GSK, Merck KGaA

Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Tags: Science, Merck, KEYTRUDA, Committee for Medicinal Products, Merck MRK

Here are two truths to help you build a successful career and future

What makes companies like Coca-Cola and Merck endure? It’s a culture that stays restless. You need that same attitude to build your career.            [Author: Special to USA TODAY]
Tags: Usa, News, Merck, Coca Cola, Special to USA TODAY

Merck 4Q net powered by cancer treatment sales, lower taxes

Higher medicine sales and lower restructuring and other costs lifted drugmaker Merck to a $1.83 billion profit in the third quarter, as it edged past Wall Street expectations. The maker of blockbuster cancer drug Keytruda and Januvia diabetes pills lost $1.05 billion a year earlier, when it had a $2.92 billion tax bill due to […]
Tags: Business, News, Merck, KEYTRUDA, Januvia

Merck quarterly profit beats estimates on Keytruda strength

Merck forecast muted 2019 revenue and earnings joining others that forecast disappointing profits for the year.
Tags: Finance, Merck, Article, Reuters, FBN, Fbn/markets, Fox-business/markets, Fox-business/markets/stocks, Fox-business/markets/earnings, Fox-business/health-care, 84ca3c1f-dc69-51e8-a438-2a7ca3826a86

UNIST researcher named as recipient of Merck’s 2018 Life Science Awards

Jun Ho Lee, a doctroral student in Life Sciences at UNIST, has been named as a recipient of Merck's 2018 Life Science Awards in Tumor Biology, receiving the grand prize of $10,000.
Tags: Health, Merck, Life Sciences, UNIST, Jun Ho Lee